HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial

Early Stage ◽

Complete Response ◽

Phase 2 ◽

Single Group ◽

Her2 Positive ◽

Open Label ◽

Multicentre Phase ◽

Phase 2 Trial ◽

Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(15)00373-3 ◽

2015 ◽

Vol 16 (16) ◽

pp. 1700-1710 ◽

Cited By ~ 65

Author(s):

Javier Cortés ◽

Véronique Dieras ◽

Jungsil Ro ◽

Jérôme Barriere ◽

Thomas Bachelot ◽

...

Keyword(s):

Breast Cancer ◽

Brain Metastases ◽

Phase 2 ◽

Her2 Positive ◽

Open Label ◽

Multicentre Phase ◽

Phase 2 Trial ◽

Choice Of Treatment ◽

Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial

BMC Medicine ◽

10.1186/s12916-018-1233-1 ◽

2019 ◽

Vol 17 (1) ◽

Cited By ~ 5

Author(s):

Joaquín Gavilá ◽

Mafalda Oliveira ◽

Tomás Pascual ◽

Jose Perez-Garcia ◽

Xavier Gonzàlez ◽

...

Keyword(s):

Liposomal Doxorubicin ◽

Pegylated Liposomal Doxorubicin ◽

Molecular Heterogeneity ◽

Phase 2 ◽

Single Group ◽

Her2 Positive ◽

Open Label ◽

Phase 2 Trial ◽

Multicenter Phase ◽

Abstract P4-14-08: Apatinib combined with docetaxel and platinum as neoadjuvant treatment for triple-negative/HER2-positive breast cancer: A randomized, open-label, multicenter, phase 2 trial

10.1158/1538-7445.sabcs19-p4-14-08 ◽

2020 ◽

Author(s):

Yunjiang Liu ◽

Shuo Zhang

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

Neoadjuvant Treatment ◽

Phase 2 ◽

Her2 Positive ◽

Open Label ◽

Phase 2 Trial ◽

Multicenter Phase ◽

HER2-enriched subtype and ERBB2 mRNA as predictors of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer: A combined analysis of TBCRC006/023 and PAMELA trials.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.509 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 509-509 ◽

Cited By ~ 8

Author(s):

Aleix Prat ◽

Carmine De Angelis ◽

TomÃ¡s Pascual ◽

Carolina Gutierrez ◽

Antonio Llombart-Cussac ◽

...

Keyword(s):

Breast Cancer ◽

Early Stage ◽

Complete Response ◽

Her2 Positive ◽

Combined Analysis ◽

Erbb2 Mrna ◽

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response

The Lancet Oncology ◽

10.1016/s1470-2045(14)70320-1 ◽

2014 ◽

Vol 15 (10) ◽

pp. 1137-1146 ◽

Cited By ~ 233

Author(s):

Evandro de Azambuja ◽

Andrew P Holmes ◽

Martine Piccart-Gebhart ◽

Eileen Holmes ◽

Serena Di Cosimo ◽

...

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Complete Response ◽

Survival Outcomes ◽

Her2 Positive ◽

Open Label ◽

Phase 3 ◽

Multicentre Phase

5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial

The Lancet Oncology ◽

10.1016/s1470-2045(16)00163-7 ◽

2016 ◽

Vol 17 (6) ◽

pp. 791-800 ◽

Cited By ~ 259

Author(s):

Luca Gianni ◽

Tadeusz Pienkowski ◽

Young-Hyuck Im ◽

Ling-Ming Tseng ◽

Mei-Ching Liu ◽

...

Keyword(s):

Breast Cancer ◽

Early Stage ◽

Randomised Trial ◽

Locally Advanced ◽

Phase 2 ◽

Her2 Positive ◽

Open Label ◽

Open Label Phase ◽

Use of [18F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [18F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(14)70475-9 ◽

2014 ◽

Vol 15 (13) ◽

pp. 1493-1502 ◽

Cited By ~ 76

Author(s):

Bruno Coudert ◽

Jean-Yves Pierga ◽

Marie-Ange Mouret-Reynier ◽

Kaldoun Kerrou ◽

Jean-Marc Ferrero ◽

...

Keyword(s):

Breast Cancer ◽

Fdg Pet ◽

Phase 2 ◽

Her2 Positive ◽

Open Label ◽

Phase 2 Trial ◽

18F Fdg ◽

Abstract P2-09-12: Independent validation of the HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer

10.1158/1538-7445.sabcs17-p2-09-12 ◽

2018 ◽

Cited By ~ 2

Author(s):

A Prat ◽

C De Angelis ◽

T Pascual ◽

C Gutierrez ◽

T Wang ◽

...

Keyword(s):

Breast Cancer ◽

Early Stage ◽

Complete Response ◽

Her2 Positive ◽

Independent Validation ◽

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(11)70336-9 ◽

2012 ◽

Vol 13 (1) ◽

pp. 25-32 ◽

Cited By ~ 1133

Author(s):

Luca Gianni ◽

Tadeusz Pienkowski ◽

Young-Hyuck Im ◽

Laslo Roman ◽

Ling-Ming Tseng ◽

...

Keyword(s):

Breast Cancer ◽

Locally Advanced ◽

Phase 2 ◽

Efficacy And Safety ◽

Her2 Positive ◽

Open Label ◽

Phase 2 Trial ◽

Open Label Phase ◽

Faculty Opinions recommendation of Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718020296.793478787 ◽

2013 ◽

Author(s):

Arthur Kim

Keyword(s):

Hepatitis C ◽

Phase 2 ◽

Genotype 1 ◽

Hepatitis C Infection ◽

Open Label ◽

Multicentre Phase ◽

Phase 2 Trial ◽

Treatment Naïve ◽

Peginterferon Alfa ◽

Ns3 Protease